Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2024 Financial Results

Rhea-AI Summary

Perspective Therapeutics (NYSE AMERICAN: CATX), a radiopharmaceutical company focusing on advanced cancer treatments, has announced it will release its Q2 2024 financial results and provide a business update on August 12, 2024, after market close. The company, which specializes in pioneering treatment applications for various cancers, will make the press release available on their website's newsroom section. This announcement signals an important upcoming disclosure for investors and stakeholders, potentially offering insights into the company's financial performance and operational progress in the rapidly evolving field of radiopharmaceuticals.

News Market Reaction

+3.01%

1 alert

+3.01% News Effect

On the day this news was published, CATX gained 3.01%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

SEATTLE, July 22, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that it will report its second quarter 2024 financial results and provide a business update on Monday, August 12, 2024 after the market closes.  The press release will be available on the newsroom section of the Company’s website at https://perspectivetherapeutics.com/newsroom/press-releases.

About Perspective Therapeutics, Inc.
Perspective Therapeutics, Inc., is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has proprietary technology that utilizes the alpha emitting isotope ²¹²Pb to deliver powerful radiation specifically to cancer cells via specialized targeting peptides. The Company is also developing complementary imaging diagnostics that incorporate the same targeting peptides, which provide the opportunity to personalize treatment and optimize patient outcomes. This "theranostic" approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity.

The Company's melanoma (VMT01) and neuroendocrine tumor (VMT-α-NET) programs have entered Phase 1/2a imaging and therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at several leading academic institutions. The Company has also developed a proprietary ²¹²Pb generator to secure key isotopes for clinical trial and commercial operations.

For more information, please visit the Company's website at www.perspectivetherapeutics.com.

FAQ

When will Perspective Therapeutics (CATX) release its Q2 2024 financial results?

Perspective Therapeutics (CATX) will release its Q2 2024 financial results on August 12, 2024, after the market closes.

Where can I find Perspective Therapeutics' (CATX) Q2 2024 financial results press release?

The Q2 2024 financial results press release will be available on the newsroom section of Perspective Therapeutics' website at perspectivetherapeutics.com/newsroom/press-releases.

What type of company is Perspective Therapeutics (CATX)?

Perspective Therapeutics (CATX) is a radiopharmaceutical company that pioneers advanced treatment applications for cancers throughout the body.

On which stock exchange is Perspective Therapeutics (CATX) listed?

Perspective Therapeutics (CATX) is listed on the NYSE American stock exchange.